Safety and Efficacy of VDPHL01 in Males With AGA
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
In the register
The register attaches this trial to VDPHL-01 (oral minoxidil) (Veradermics), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 3
- Sponsor
- Veradermics, Inc.
- Participants (registry)
- 480
- Start
- March 2025
- Primary completion
- December 2026 (planned)
- Study completion
- July 2027 (planned)
- Last registry update
- February 2026
- Countries
- United States
Conditions studied: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01, Placebo
Other trials of VDPHL-01 (oral minoxidil)
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Efficacy and Safety of VDPHL01 in Males With AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.